Aptose Bioscns (APTO)

$0.21 +0.01 (3.33%)
Market Cap 12.46M
Revenue (ttm) 0.00
Net Income (ttm) -51.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.10
Volume 263,300
Avg Vol 8,285,948
Day's Range N/A - N/A
Shares Out 60.18M
Stochastic %K 31%
Beta 0.87
Analysts Strong Sell
Price Target $8.67

Latest News on APTO

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Jan 9, 2025, 4:00 PM EST - 8 days ago

Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Dec 19, 2024, 4:05 PM EST - 4 weeks ago

Aptose Announces Positive Decision by Nasdaq Hearings Panel

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Dec 12, 2024, 10:15 AM EST - 5 weeks ago

Aptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with Venetoclax

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Dec 9, 2024, 12:00 PM EST - 5 weeks ago

Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Dec 3, 2024, 7:30 AM EST - 6 weeks ago

Aptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine Trials

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Nov 25, 2024, 4:15 PM EST - 7 weeks ago

Aptose Biosciences Inc. Announces Closing of $8 Million Public Offering

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Nov 22, 2024, 8:00 AM EST - 2 months ago

Aptose Biosciences Inc. Announces Pricing of $8 Million Public Offering

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Nov 20, 2024, 7:30 AM EST - 2 months ago

Aptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy

Aptose Reports Results for the Third Quarter 2024

Nov 8, 2024, 4:01 PM EST - 2 months ago

Aptose Reports Results for the Third Quarter 2024

Aptose Announces Results from Special Meeting of Shareholders

Sep 5, 2024, 4:15 PM EDT - 4 months ago

Aptose Announces Results from Special Meeting of Shareholders

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aug 30, 2024, 4:30 PM EDT - 5 months ago

Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aug 15, 2024, 4:30 PM EDT - 5 months ago

Aptose Announces Adjournment of its Special Meeting of Shareholders

Aptose Reports Results for the Second Quarter 2024

Aug 8, 2024, 5:06 PM EDT - 5 months ago

Aptose Reports Results for the Second Quarter 2024

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Jul 19, 2024, 5:00 PM EDT - 6 months ago

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Announces Results from Annual and Special Meeting of Shareholders

Jun 18, 2024, 5:30 PM EDT - 7 months ago

Aptose Announces Results from Annual and Special Meeting of Shareholders

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Jun 14, 2024, 7:30 AM EDT - 7 months ago

Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 3, 2024, 4:30 PM EDT - 8 months ago

Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

May 31, 2024, 8:00 AM EDT - 8 months ago

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

May 14, 2024, 11:12 PM EDT - 8 months ago

Aptose Biosciences Inc. (APTO) Q1 2024 Earnings Call Transcript

Aptose Reports Results for the First Quarter 2024

May 14, 2024, 4:01 PM EDT - 8 months ago

Aptose Reports Results for the First Quarter 2024

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

May 6, 2024, 4:30 PM EDT - 9 months ago

Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

Mar 26, 2024, 8:38 PM EDT - 10 months ago

Aptose Biosciences Inc. (APTO) Q4 2023 Earnings Call Transcript

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Mar 26, 2024, 4:01 PM EDT - 10 months ago

Aptose Reports Results for the Fourth Quarter and Full Year 2023

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Mar 18, 2024, 4:30 PM EDT - 10 months ago

Aptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Jan 31, 2024, 4:01 PM EST - 1 year ago

Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Jan 26, 2024, 8:00 AM EST - 1 year ago

Aptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi Pharmaceutical

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Dec 9, 2023, 6:30 PM EST - 1 year ago

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Nov 30, 2023, 4:59 PM EST - 1 year ago

Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 7:22 PM EST - 1 year ago

Aptose Biosciences Inc. (APTO) Q3 2023 Earnings Call Transcript

Aptose Reports Results for the Third Quarter 2023

Nov 9, 2023, 4:00 PM EST - 1 year ago

Aptose Reports Results for the Third Quarter 2023

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Oct 30, 2023, 9:15 AM EDT - 1 year ago

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

Oct 26, 2023, 7:11 AM EDT - 1 year ago

Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Oct 23, 2023, 7:30 AM EDT - 1 year ago

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Oct 16, 2023, 7:30 AM EDT - 1 year ago

Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference

Aptose to Present at the Cantor Global Healthcare Conference

Sep 18, 2023, 7:45 AM EDT - 1 year ago

Aptose to Present at the Cantor Global Healthcare Conference

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Sep 6, 2023, 7:45 AM EDT - 1 year ago

Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 24, 2023, 7:30 AM EDT - 1 year ago

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 11:01 PM EDT - 1 year ago

Aptose Biosciences Inc. (APTO) Q2 2023 Earnings Call Transcript

Aptose Reports Results for the Second Quarter 2023

Aug 10, 2023, 4:02 PM EDT - 1 year ago

Aptose Reports Results for the Second Quarter 2023

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

Jul 27, 2023, 4:04 PM EDT - 1 year ago

Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Jun 26, 2023, 4:05 PM EDT - 1 year ago

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Presents Highlights from Clinical Update

Jun 10, 2023, 12:00 PM EDT - 1 year ago

Aptose Presents Highlights from Clinical Update

Aptose Biosciences Provides Update on Reverse Stock Split

Jun 5, 2023, 7:30 AM EDT - 1 year ago

Aptose Biosciences Provides Update on Reverse Stock Split

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

May 31, 2023, 7:30 AM EDT - 1 year ago

Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023

Aptose Enters into $25 Million Committed Equity Facility

May 25, 2023, 4:14 PM EDT - 1 year ago

Aptose Enters into $25 Million Committed Equity Facility

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

May 23, 2023, 5:30 PM EDT - 1 year ago

Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders

Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript

May 8, 2023, 9:22 PM EDT - 1 year ago

Aptose Biosciences Inc. (APTO) Q1 2023 Earnings Call Transcript

Aptose Reports Results for the First Quarter 2023

May 8, 2023, 4:01 PM EDT - 1 year ago

Aptose Reports Results for the First Quarter 2023

Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference

May 4, 2023, 7:01 AM EDT - 1 year ago

Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference